Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition containing butyphthalide as well as application of pharmaceutical composition in preparing medicines for treating cerebrovascular diseases

A composition, the technology of butylphthalide, applied in the direction of drug combination, medical preparations containing active ingredients, cardiovascular system diseases, etc., can solve the problems of inability to drive normal functions, lack of energy supply, etc., and achieve effective ischemia For cerebrovascular disease and dementia, the effect of reducing the dosage and increasing the therapeutic effect

Active Publication Date: 2018-01-19
SHIJIAZHUANG PHARMA GRP NBP PHARMA CO LTD
View PDF6 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Due to the blockage of cerebral blood flow and lack of energy supply, the original normal function cannot be performed

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing butyphthalide as well as application of pharmaceutical composition in preparing medicines for treating cerebrovascular diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Embodiment 1: Preparation of composition liquid.

[0029] (1) Preparation of butylphthalide liquid

[0030] Take 1000g of butylphthalide, add 1000g of HS-15 (polyethylene glycol 15 hydroxystearate), fully stir and dissolve, and the butylphthalide liquid is obtained.

[0031] (2) Preparation of methylcobalamin liquid

[0032] Take 5g of methylcobalamin, add 495g of propylene glycol, and stir until the liquid is clear, which is methylcobalamin liquid.

[0033] (3) Preparation of butylphthalide + methylcobalamin solution

[0034] Take the butylphthalide medicinal solution and the methylcobalamin medicinal solution in a given ratio, and mix them evenly to obtain the product. The mixing ratio is as follows:

[0035] .

[0036] The above medicinal liquid can be further added with pharmaceutically acceptable auxiliary materials, and compressed into soft capsules by conventional methods such as CN1623542.

Embodiment 2

[0037] Embodiment 2: Preparation of the composition liquid.

[0038] (1) Preparation of L-butylphthalide liquid medicine

[0039] Take 1000g of L-butylphthalide, add 1000g of HS-15 (polyethylene glycol 15 hydroxystearate), stir well to dissolve, and it is butylphthalide liquid.

[0040] (2) Preparation of methylcobalamin liquid

[0041] Get methylcobalamin 5g, add propylene glycol 495g, stir until liquid medicine Clarified, it is methylcobalamin liquid.

[0042] (3) Preparation of L-butylphthalide + methylcobalamin liquid

[0043] Take the L-butylphthalide medicinal solution and the methylcobalamin medicinal solution in a given ratio, and mix them evenly to obtain the product. The mixing ratio is as follows:

[0044] .

[0045] The above medicinal liquid can be further added with pharmaceutically acceptable auxiliary materials, and compressed into soft capsules by conventional methods such as CN1623542.

Embodiment 3

[0046] Embodiment 3: mouse global ischemia test

[0047] 1 Animal experiment materials

[0048] 1.1 Drugs: The tested drugs are: butylphthalide (racemic butylphthalide) liquid prepared in Example 1, methylcobalamin liquid, butylphthalide+methylcobalamin composition liquid, levorotatory liquid prepared in Example 2 Butylphthalide medicinal solution, L-butylphthalide + methylcobalamin composition medicinal solution, model control is 0.9% normal saline.

[0049] 1.2 Animals: SPF grade KM mice, male, 18-22 grams, provided by the Experimental Animal Center of Hebei Medical University; the experimental animal production license number is SCXK (Ji) 2013-1-003. Experimental animal use license number: SYXK (Ji) 2011-0059.

[0050] 1.3 Data processing: The data were analyzed by variance analysis and inter-group test by SPSS11.5 statistical software.

[0051] 2 Mice global cerebral ischemia test

[0052] 2.1 Animal grouping and administration: 150 Kunming mice were randomly divided i...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pharmaceutical composition, which consists of butyphthalide and mecobalamine. The pharmaceutical composition, when used for treating cerebrovascular diseases and dementia, can achieve a synergistic effect, wherein with the adoption of the mecobalamine, the therapeutic effect of the butyphthalide can be obviously enhanced, so that the effective dosage of the butyphthalideis reduced and a using dose is reduced; and the pharmaceutical composition, when used for a long time, can reduce the occurrence of adverse reactions. Therefore, the pharmaceutical composition can take a more effective on treating the cerebrovascular diseases and dementia, and a therapeutic effect can be achieved at a relatively low dose, so that the pharmaceutical composition is suitable for clinical application.

Description

technical field [0001] The invention belongs to the technical field of pharmaceutical compositions, and in particular relates to a pharmaceutical composition containing butylphthalide and its application. Background technique [0002] With the rapid development of the economy, people's living conditions and lifestyles have changed significantly, coupled with the rapid aging of the population, resulting in great changes in the national disease spectrum and death spectrum. At present, cerebrovascular disease has become a major disease that endangers the health and life of middle-aged and elderly people in my country. Cerebrovascular disease (CVD) is a brain lesion caused by cerebrovascular abnormalities. Stroke generally refers to acute cerebrovascular disease. According to the population monitoring data released by the Statistics Center of the Ministry of Health, whether it is urban or rural, In recent years, cerebrovascular disease has shown a significant forward trend in t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/714A61K31/365A61P9/10A61P25/28
Inventor 牛锋王振国齐军彩焦魁良韩春景郭聪聪刘光
Owner SHIJIAZHUANG PHARMA GRP NBP PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com